Of note, out of the sixteen patients with osteosarcoma, 43.8% (7/16) exhibited a TP53 mutation, 43.8% (7/16) exhibited a C17orf39 mutation, 31.3% (5/16) exhibited a CCNE1 mutation, and 25% (4/16) exhibited an RB1 mutation. This evidence concerns the gene TP53 and osteosarcoma.